Amyotrophic Lateral Sclerosis (ALS) Genetics and Microbiota: A Comprehensive Review - PubMed
5 hours ago
- #genetics
- #microbiota
- #ALS
- ALS is a severe neurodegenerative disorder affecting motor neurons, with a median survival of 2 to 5 years.
- ALS shares clinicopathological features with Frontotemporal Dementia (FTD) due to overlapping molecular processes like oxidative stress and TDP-43 proteinopathy.
- Key genetic factors in ALS include mutations in C9orf72, SOD1, TARDBP, and FUS, with Tofersen being an approved SOD1-specific gene therapy.
- The gut-brain connection is significant in ALS, with dysbiosis and lower neuroprotective metabolites like nicotinamide influencing disease progression.
- Treatment strategies are shifting toward personalized approaches, including gene therapies (ASOs, RNAi, CRISPR) and microbiome-modulating treatments (probiotics, FMT).
- Microbiome and gene therapies, though experimental, show promise, as seen with the approval of Tofersen.